David Bleakman received his PhD in Physiology from King’s College, University of London. As a post-doctoral fellow at the University of Chicago, he studied neuropeptide modulation of voltage-dependent calcium channels and the role of glutamate receptors in neuronal function. He joined Eli Lilly and Company in 1993 in the U.K. as a scientist in the Neuroscience Division where his work focused on the discovery and development of novel therapeutic agents for the treatment of neurological and psychiatric disorders. In, 1998, he moved to Lilly in Indianapolis where he is currently an Executive Director and Chief Scientific Officer of the psychiatric disorders research team.